Alternative splicing of pre-mRNA is a fundamental mechanism of differential gene expression in that it can give rise to functionally distinct proteins from a single gene, according to the developmental or physiological state of cells in multicellular organisms. In the pre-mRNA of the cell surface molecule CD44, the inclusion of up to 10 variant exons (v1-v10) is regulated during development, upon activation of lymphocytes and dendritic cells, and during tumour progression. Using minigene constructs containing CD44 exon v5, we have discovered exonic RNA elements that couple signal transduction to alternative splicing. They form a composite splice regulator encompassing an exon recognition element and splice silencer elements. Both type of elements are necessary to govern cell typespecific inclusion of the exon as well as inducible inclusion in T cells after stimulation by concanavalin A, by Ras signalling or after activation of protein kinase C by phorbol ester. Inducible splicing does not depend on de novo protein synthesis. The coupling of signal transduction to alternative splicing by such elements probably represents the mechanism whereby splice patterns of genes are established during development and can be changed under physiological and pathological conditions.
Introduction
In multicellular organisms, alternative pre-mRNA splicing can give rise to functionally distinct proteins from a single gene. It can be regulated dependent on sex (Baker, 1989; Rio, 1993) , developmental stage or tissue (Rio, 1993; Sharp, 1994; Wang and Manley, 1997) and in response to extracellular stimuli such as growth factors (Wang et al., 1991; Shifrin and Neel, 1993; Metheny and Skuse, 1996; Fichter et al., 1997) , hormones (Kosaki and Webster, 1993; Chalfant et al., 1995; Metheny and Skuse, 1996) , cytokines (Mackay et al., 1994; McKay et al., 1994; Eissa et al., 1996) , extracellular pH (Borsi et al., 1995) or membrane depolarization (Zacharias and Strehler, 1996) . Alternative splicing is thus a fundamental mechanism of differential gene expression. Coupling of pre-mRNA splicing to extracellular signals is not only crucial for 2904 © Oxford University Press altering splice patterns according to the physiological state of cells but it may also be important in establishing and changing splice patterns during development and cell differentiation. In contrast to cis-acting DNA elements in promoters and enhancers of genes that are able to regulate transcription in an inducible manner, signal-responsive RNA elements and the mechanism whereby alternative pre-mRNA splicing is linked to cell signalling are as yet unknown. We have addressed this important issue by investigating alternative pre-mRNA splicing of the cell surface molecule CD44, which is regulated both in a cell type-specific manner and in response to extracellular stimuli. Alternative splicing generates variant CD44 isoforms by the inclusion of up to 10 variant exons (v1-v10) during embryonic development and during tumour progression (reviewed in Sherman et al., 1996) , as well as upon activation of lymphocytes (Arch et al., 1992; Koopman et al., 1993; Mackay et al., 1994; Screaton et al., 1995) and dendritic cells (Weiss et al., 1997) . In an attempt to understand the mechanisms underlying the cell type-specific and inducible inclusion of CD44 variant exons, we have sought to identify splice regulatory elements in the CD44 pre-mRNA. We report here on the identification of a composite exonic splice control unit which combines an exon recognition element with splice silencer elements and which governs alternative splicing in a cell type-specific manner and in response to activation of protein kinase C (PKC) or Ras signalling pathways. The discovery of signal-responsive splice elements provides a link between extracellular signals and differential gene expression through alternative pre-mRNA splicing.
Results and discussion
The principle of the analysis In a previous study, we showed by cell fusion experiments that alternative splicing of CD44 is controlled by transacting factors (König et al., 1996) . The CD44 gene spans 50 kb, and multiple variant exons can be included by alternative splicing in various combinations (Screaton et al., 1992; Tölg et al., 1993) . To explore how individual exons are selected and which sequence elements are targeted by trans-acting factors and influenced by extracellular stimuli, we reduced the complexity of the CD44 gene. To this end, a minigene construct was generated which carries only one variant exon plus surrounding intron sequences in an exon-trap vector. Our approach was first to transfect the minigene into cell lines which differ in CD44 variant exon inclusion in order to test whether the variant exon of the minigene is alternatively spliced in the same way as the variant exon of the endogenous CD44 gene. If so, mutation analyses of the minigene should then be used to define sequence elements which regulate alternative splicing. Two conditions were to be met: the selection of suitable recipient cell lines and the choice of a variant exon for the minigene construct whose endogenous counterpart was under pronounced regulation and which, in the minigene context, was still alternatively spliced.
Cell type-specific and inducible alternative splicing of CD44 pre-mRNA
We chose a cell line that constitutively expresses CD44 variant isoforms, the murine carcinoma cell line KLN205, and a cell line which shows inducible expression of variant isoforms, the mouse T-lymphoma cell line LB17 2.3. As shown by exon-specific PCR analysis (see Figure 1A) , the KLN205 carcinoma cell line expresses predominantly CD44 variant mRNAs ( Figure 1B , lanes 11 and 12), including one RNA species that carries all variant exon sequences, v1-v10 ( Figure 1B, lanes 1-10) . In contrast, in the T-lymphoma line LB17 2.3, variant exons are skipped, giving rise almost exclusively to mRNA lacking variant exon sequences ( Figure 1C , upper panel, lane 11). Expression of transcripts carrying single exon sequences of v1, v4, v7 or v10 were only weakly detectable (lanes 1, 4, 7 and 10). Inclusion of variant exons was, however, induced upon treatment of the LB17 cells with the phorbol ester 12-o-tetradecanoylphorbol-13-acetate (TPA) and the calcium ionophore ionomycin. Although representing only a fraction of total CD44 mRNA, transcripts with single exon sequences of either v1, v3, v4, v5, v7 or v10 were now easily detectable ( Figure 1C , lower panel, lanes 1, 3-5, 7 and 10). In addition, one transcript occurred in which exon v4 is linked to an additional downstream exon (lane 4).
A minigene model for cell type-specific and signal-induced alternative splicing
For the minigene construct to be used for transfection into the two cell lines and for the subsequent identification of regulatory splice elements, we chose CD44 exon v5. We found this exon frequently to be included during tumour progression and upon T-cell activation, and its inclusion was tightly regulated by phorbol ester in the T-cell line to be used as one of the recipients (see Figure 1C ). A part of the murine genomic CD44 region including exon v5 and intron sequences on either side was cloned into the exon-trap vector pL53In, between the pre-proinsulin exons 2 and 3 and their adjacent intron sequences (see Figure 2A ). The insulin exons provided a means of distinguishing the minigene transcripts from the endogenous CD44 mRNA.
To test whether the CD44 exon v5 of the minigene was alternatively spliced according to exon v5 of the endogenous CD44 gene, the minigene construct was transiently transfected into the two cell lines which differ in CD44 v5 exon inclusion. Because of the low transfection efficiency of the cell lines, transcripts from the minigene constructs were analysed by RT-PCR. PCR primers were derived from the insulin exons (see Figure 2A ). In the KLN205 carcinoma cells, the vast majority of the minigene mRNA included the CD44 exon v5 sequence, whereas in the LB17 T-lymphoma cell line exon v5 was predominantly absent ( Figure 2B ). Co-regulation of exon inclusion and exon skipping in the minigene mRNA and in the endogenous CD44 mRNA was also observed in human cell (Tölg et al., 1993) ; lines, intron sequences. Endogenous CD44 transcripts were analysed by exon-specific RT-PCR in (B) mouse KLN205 carcinoma cells and (C) mouse LB17 2.3 T-lymphoma cells treated with TPA (40 ng/ml) plus ionomycin (0.4 µg/ml) for 20 h (TPAϩIon) or, as a control (C), with DMSO. Exon-specific PCRs were performed using the 5Ј primers specific for the variant exons indicated (lanes 1-10) and the constant region 5Ј primer c13 (lanes 11 and 12), respectively, in combination with the 3Ј C2A primer (König et al., 1996) . Lane 12 in (B) shows a longer exposure of lane 11. CD44 mRNA lacking all variant exons gives rise to a 594 bp PCR product. M ϭ 123 bp ladder (Life Technologies). Asterisks denote an unspecific PCR product (König et al., 1996) . All PCR products were resolved on ethidium bromide-containing 2% agarose gels and visualized by UV irradiation. lines: exon skipping in 293 embryonic kidney cells and in KG-1 acute myelogenic leukaemia cells versus exon inclusion in HaCaT keratinocytes or in HT-3 cervix carcinoma cells (data not shown). Thus, in the minigene pre-mRNA, the exon v5 sequence is included or skipped in a cell type-specific manner, similarly to the v5 sequence of the endogenous CD44 pre-mRNA. Furthermore, activation of the LB17 T-lymphoma cell line by TPA resulted (Tölg et al., 1993) (top) . To reduce complexity, exon v4 was deleted. RSV, Rous sarcoma virus; MCS, multiple cloning site; SV40 PolyA, simian virus 40 polyadenylation sequence. Symbols for genomic CD44 region are as in the legend to Figure 1 . Arrowheads indicate the positions of the primers used for RT-PCR in (B) and (C). Skipping of exon v5 results in a 244 bp PCR product, and v5 inclusion in a 361 bp product. After transient transfection, inclusion of exon v5 in minigene transcripts was analysed by RT-PCR of cytoplasmic RNA prepared from (B) KLN205 carcinoma cells and LB17 2.3 T-lymphoma cells and (C) LB17 2.3 T-lymphoma cells treated as indicated for 7 h. In lanes 12 and 13, the minigene construct was co-transfected with either an empty expression plasmid (RSV) or a plasmid expressing the activating Ha-ras mutant Leu61 (RSV Ha-ras) (Medema et al., 1991) . M, 123 bp ladder (Life Technologies); C, control (DMSO); TPA (40 ng/ml); Ion, ionomycin (0.4 µg/ml); An, anisomycin (100 µM); CHX, cycloheximide (100 µg/ml); CsA, cyclosporin A (1 µg/ml); ConA, concanavalin A (14 µg/ml).
in a marked enhancement of exon v5 inclusion ( Figure  2C , lanes 1 and 2), again reflecting the splicing behaviour of the endogenous CD44 v5 exon. Inclusion of exon v5 was also induced by treatment of LB17 cells with concanavalin A ( Figure 2C , lane 11), a lectin that triggers T-cell activation (Tsien et al., 1982) . Ionomycin, known to synergize with phorbol esters in T-cell activation (Truneh et al., 1985) , did not induce exon inclusion and did not enhance the degree of inclusion triggered by TPA treatment alone, neither in the minigene nor in the endogenous gene transcripts ( Figure 2C , lanes 3 and 4; and data not shown). Consistent with this finding, cyclosporin A, which inhibits a calcium-dependent step in T-cell activation (Liu et al., 1991) , did not affect exon inclusion upon treatment by TPA plus ionomycin ( Figure  2C , lanes 9 and 10). We can thus conclude that the minigene is suitable for analysing both cell type-specific and signal-induced alternative splicing of CD44 exon v5.
Protein synthesis-independent activation of CD44 v5 exon inclusion
To investigate whether the activation of alternative splicing depends on de novo protein synthesis, we tested phorbol ester inducibility of v5 exon inclusion in the presence of the protein synthesis inhibitors anisomycin or cycloheximide. When applied alone, both inhibitors stimulated exon inclusion to some extent ( Figure 2C, lanes 5 and 7) . This could be due to activation of the mitogen-activated kinase (MAPK) and stress-activated kinase (SAPK) cascades by these inhibitors (Zinck et al., 1995; Iordanov et al., 1997) . Additional treatment with TPA and ionomycin, however, resulted in markedly higher levels of v5 exon inclusion ( Figure 2C , lanes 6 and 8), comparable with the level obtained after TPA/ionomycin treatment alone ( Figure 2C , lane 4). Thus, neither inhibitor impaired phorbol esterinduced exon inclusion, suggesting that post-translational modifications of pre-existing splice regulatory factors rather than the expression of new factors are involved. Similarly, changes of splice patterns during neural induction (neural-specific c-src mRNA; Collett and Steele, 1993) and in response to elevated intracellular Ca 2ϩ (plasma membrane Ca-ATPase; Zacharias and Strehler, 1996) do not require protein synthesis. In contrast, growth factor-induced generation of phosphotyrosine phosphatase PTP-1B-mRNA isoforms has been reported to depend on de novo protein synthesis (Shifrin and Neel, 1993) .
Activation of alternative splicing by Ras
Phorbol esters are not physiological activators of T cells. Their action on exon inclusion indicates, however, that signalling pathways involving the phorbol ester target PKC (Castagna et al., 1982) can regulate alternative splicing. PKC is known to be a downstream signalling molecule of the T-cell receptor and to activate p21 ras in T cells (Valge et al., 1988; Downward et al., 1990) . Activation of p21 ras can also be achieved by PKCindependent mechanisms and seems to be a necessary step in T-cell activation (Cantrell, 1996) . To test whether activation of p21 ras can induce inclusion of CD44 exon v5, we transfected the minigene into LB17 cells together with either a plasmid expressing activated Ha-Ras or the empty expression vector. Figure 2C (lanes 12 and 13) shows that activated p21 ras indeed induces v5 exon inclusion, indicating coupling of Ras signalling pathways to alternative splicing. Since mutational activation of ras genes is a frequent event in human tumours (Rodenhuis, 1992) , Ras signalling may also account for the expression of variant CD44 isoforms observed during tumour progression of certain human tumours (Sherman et al., 1996) .
Cell type-specific and inducible splice regulatory elements in CD44 exon v5
The results described above suggest that regulatory sequences necessary for both cell type-specific and inducible splicing of CD44 exon v5 are present in the genomic CD44 sequences of the minigene construct. To identify these regulatory sequences, we generated deletion and linker-scan mutants. Deletion of intron sequences upstream or downstream of exon v5 (leaving 5Ј and 3Ј splice sites intact) did not affect splice regulation in KLN205 carcinoma cells (data not shown), suggesting that the CD44 intron sequences contain no elements necessary for v5 exon inclusion. We therefore tested the possibility that sequences within the alternatively spliced exon itself governed exon inclusion. With this reasoning, the CD44 v5 exon sequence was replaced by unrelated sequences of approximately the same length from either a polylinker region (v5blue) or the bacterial ampicillin resistance gene (v5amp; see Figure 3A ). The four 5Ј most and the three 3Ј most base pairs of exon v5 were maintained in these substituted exons to leave the splice sites unchanged. (That the splice sites remain functional is demonstrated below by the linker-scan mutants ls1 and ls11 which are spliced efficiently; see Figure 4A and B.) Both substituted exons were no longer included in the minigene mRNA, neither in KLN205 cells ( Figure 3B ) nor in TPA-treated LB17 cells ( Figure 3C ). Thus, exon v5 contains sequences necessary for both cell type-specific and inducible alternative splicing.
Linker-scan mutations define distinct regulatory elements in exon v5
To identify the sequences within exon v5 that govern alternative splicing, we generated linker-scan (ls) mutants by consecutively replacing 10 bp segments within the 117 bp v5 exon by a 10 bp linker sequence ( Figure 4A ). Again, the exon ends were left unchanged as in the substitution mutants. After transient transfection into KLN205 cells, mutations ls1-ls8 and ls10 did not impair exon v5 inclusion. Mutation ls9 and, to a somewhat lesser extent, ls11 inhibited exon v5 inclusion as compared with the unmutated v5 exon ( Figure 4B ). Moreover, in LB17 lymphoma cells which spontaneously omit v5 (see Figure  2B ), the ls9 mutant decreased the low basal level of exon inclusion even further and almost completely abolished TPA inducibility ( Figure 4C ). Mutant ls11 also impaired induction of exon inclusion upon phorbol ester treatment. Thus, the two mutants, ls9 and ls11, apparently interrupted positively acting splice regulatory sequences in the 3Ј region of the exon.
Interestingly, all ls mutations upstream of ls9, except for ls5, resulted in strong enhancement of exon inclusion in LB17 cells in the absence of TPA ( Figure 4C ) which could not be markedly increased by TPA. The strong enhancement of v5 inclusion is not due to a splice enhancer activity of the linker sequence since ls5 does not show this up-regulation, and a mutant containing a deletion instead of the linker in the position of ls7 had the same effect as the potent ls7 linker-scan mutant (data not shown). These findings indicate the existence of splice silencer elements upstream of ls9 which repress exon inclusion in non-stimulated LB17 cells. These silencers appear to be inactive in KLN205 cells and to be inactivated upon TPA treatment of LB17 cells. The minor effect of these mutants in the KLN205 cells ( Figure 4B) is consistent with the already very high level of CD44 exon v5 inclusion in these cells (see Figure 2B ).
The exon recognition element
The finding that the ls9 and ls11 mutations individually did not completely inhibit exon inclusion in KLN205 cells (see Figure 4B ) suggested that changing 10 bp in this positively acting region might not suffice to prevent splice activation completely. This may be due to a high abundance of binding factors in these cells so that an insufficiently mutated binding site could still be recognized to some extent. According to this hypothesis, the functional loss should be more pronounced if the positively acting region were removed completely. We therefore deleted 40 bp, including the sequences affected by the ls9 and ls11 mutations, from the 3Ј region of exon v5, maintaining, as in previous constructs, the three 3Ј most nucleotides (see Figure 5A , mutant ∆R). This deletion completely abolished exon inclusion in the KLN205 cells ( Figure 5A, lane 4) and in TPA-treated LB17 cells ( Figure 5A, lanes 11 and  12) . The loss of exon inclusion is not due merely to the change in exon length since replacing the 3Ј region by a polylinker sequence of the same length has the same effect (see Figure 5C , mutant ∆Rblue, lanes 5 and 6; data not shown for KLN205 cells). Thus, the 3Ј 40 bp of the exon seem to be absolutely necessary for exon recognition. Interestingly, the sequences within this region which are replaced in the ls9 and ls11 mutants (see Figure 4A ) are very similar to purine-rich sequence elements (so-called exon recognition sequences) (Watakabe et al., 1993; Tanaka et al., 1994) and A/C-rich splicing enhancers (Coulter et al., 1997) , respectively. Purine-rich elements are known to bind members of the family of serine/ arginine-rich (SR) proteins (Fu, 1995; Manley and Tacke, 1996; Valcarel and Green, 1996) , which is possibly also true for the exon recognition element in exon v5.
The linker-scan mutations in the 5Ј region of the v5 exon suggest that the positive element(s) in the 3Ј part of the exon suffice to retain the exon in the transcript. We have confirmed the autonomy of the enhancer elements by placing the 3Ј 40 bp into the artificial polylinkersubstituted v5blue exon (see Figure 3 and Figure 5B , lanes 3 and 4) to create a chimaeric exon (v5bls7; see Figure 5B ). This chimaeric exon was now included very efficiently in both KLN205 (not shown) and in LB17 lymphoma cells ( Figure 5B ), indicating that the 3Ј 40 bp of CD44 exon v5 indeed act as an exon recognition element. Inclusion of the chimaeric exon in the LB17 lymphoma cells occurred already without phorbol ester stimulation ( Figure 5B, lanes 5 and 6) . This result suggests that both cell type-specific and inducible exon usage require v5 sequences upstream of the exon recognition element which, in the v5bls7 exon, were replaced by polylinker sequences. Furthermore, the finding confirms the result of the linker-scan analysis (see Figure 4C ) which also suggested negative regulatory sequences in this region.
Silencer elements are necessary for cell type-specific and inducible exon usage
Interestingly, all linker-scan mutants within the stretch of 80 bp upstream of the exon recognition sequence resulted in constitutive exon inclusion, with the exception of ls5. The linker-scan mutations in this region apparently fall into two areas separated by ls5. Both areas in the wildtype exon configuration participate in suppressing exon usage. To test whether the two areas indeed represent two regulatory subdomains in the 80 bp silencer region, we generated 40 bp deletions in either the 5Ј ('left') part (subdomain L, whereby the four 5Ј most base pairs were maintained) or the 'middle' part (subdomain M) of the exon (see mutants ∆L and ∆M, Figure 5A ). Whereas, as expected from the linker-scan analysis, deletion of subdomain L resulted in a high level of exon inclusion in the LB17 T-lymphoma cells, which can only be enhanced slightly by TPA treatment (Figure 5A, lanes 7 and 8) , deletion of subdomain M did not impair regulation of exon inclusion ( Figure 5A, lanes 9 and 10) . Thus, in contrast to subdomain M, subdomain L suffices to keep the basal level of exon inclusion low and allows regulated exon inclusion in this setting. This result is at variance with the results of the linker-scan analysis: linker-scan mutants in subdomain M led to constitutive v5 exon usage (see ls6-8, Figure 4C ).
The discrepancy between linker-scan mutants and deletion of subdomain M led us to postulate that subdomain M exerted a specific function in conjunction with sub-2909 domain L. This function would be needed for regulation only if subdomain L were located at its original position, 40 bp apart from the exon recognition element (subdomain R, see previous paragraph). To test this assumption, we moved subdomain L back to its original position by inserting 40 bp of polylinker sequence between the L and R subdomains (mutant ∆Mblue, see Figure 5C ). Subdomain L was now no longer sufficient to regulate exon inclusion ( Figure 5C, lanes 3 and 4) , suggesting that, within the complete exon, subdomain M is required together with subdomain L to regulate exon usage. Possibly, the cooperating components of the composite splice unit must be direct neighbours in order to form a functional complex.
Silencer versus enhancer: which element responds to signal transduction?
The substitution mutants in the silencer region indicated that the silencer sequences are necessary for regulated exon inclusion since these mutants resulted in constitutive exon usage (see Figure 5B and C). However, the mutants do not allow distinction between whether the silencer elements respond to phorbol ester and the 3Ј enhancer element acts only in a constitutive manner, or whether the activity of the 3Ј enhancer is modulated by phorbol ester activation. To test whether the 3Ј enhancer can respond to phorbol ester activation, we generated a mutant exon that, like the v5bls7 exon (see Figure 5B ), contained no silencer sequences but, due to a reduction in exon size, should be recognized less efficiently. Figure 6A shows that a mini-exon containing only the 3Ј enhancer element (v5ls1/8) is not recognized at all (lanes 3 and 4) , probably because it is too small. In contrast, a mini-exon containing the 3Ј enhancer plus 30 bp of polylinker sequence (v5ls1/8blue20) instead of 80 bp as in the v5bls7 exon (see Figure 5B ) is included to a low degree in the LB17 T-lymphoma cells ( Figure 6A, lane 5) . After TPA treatment of the cells (mutant ∆M in lanes 1 and 2 served as a positive control for TPA action), inclusion of this mini-exon is enhanced ( Figure 6A, lanes 5 and 6) , suggesting that the 3Ј enhancer element can respond to TPA activation, at least in this setting.
To investigate coupling of signal transduction to the silencer and/or enhancer sequences in the original context (full exon length), we made use of silencer substitution mutants in which subdomains L or M were replaced by a heterologous sequence of the same length (see Figure 6B) . In contrast to the ∆Lblue and ∆Mblue mutants (see Figure  5C ), these substitutions (∆La30 and ∆Ma30) did not interfere with basal repression of exon inclusion in the LB17 T-lymphoma cells ( Figure 6B, lanes 1, 3 and 5 , and Figure 6C ). The reason for this difference in behaviour of the ∆blue and the ∆a30 mutants is not clear, but it might be related to short sequence elements which we found shared between the substitution sequence of the ∆a30 mutants and subdomain L of the silencer region.
(When substituting the 3Ј enhancer region with this sequence, exon recognition was ablated, as was observed with the ∆Rblue mutant; compare Figure 6B, lanes 7 and  8, and Figure 5C , lanes 5 and 6.) Although the enhancer element is present in the silencer substitution mutants, these mutants show an impaired TPA response as compared with the wild-type exon ( Figure 6B, lanes 1-6, and Figure  Fig. 6 . The 3Ј exon recognition sequence can respond to phorbol ester-induced signal transduction in a CD44 v5 mini-exon but is not sufficient for full TPA response in the complete v5 exon. (A) RT-PCR analysis was performed from cytoplasmic RNA of LB17 T-lymphoma cells transiently transfected with the mutant constructs indicated on the left. Black boxes, v5 sequences; grey boxes, linker sequences. (B) RT-PCR analysis of the silencer substitution mutants shown on the left after transient transfection into LB17 T-lymphoma cells. Where indicated, cells were treated with TPA (40 ng/ml) for 7 h. Black boxes, CD44 exon v5 sequences; hatched boxes, a30 substitution sequence (see Materials and methods); L, M and R, 40 bp subdomains of CD44 exon v5 which were substituted as indicated. (C) Quantification of the RT-PCR analysis shown in (B). RT-PCR bands were scanned and logarithmic density values of pixel data were determined using the Adobe Photoshop programme. Results are expressed as the percentage of v5-containing RT-PCR products relative to total RT-PCR products. 6C). The result indicates that, in the context of the complete v5 exon, phorbol ester activation via the enhancer element does not suffice for the full phorbol ester response, and suggests that at least part of the TPA response is mediated by the silencer region. However, one cannot totally exclude the possibility that TPA-induced signal transduction targets the enhancer region and that the impaired TPA response is caused by a defect in enhancersilencer communication (evoked by the silencer mutation and not affecting basal communication). A role for the 3Ј enhancer element in the phorbol ester response in the complete v5 exon would be consistent with the behaviour of the linker-scan mutants ls9 and ls11, which showed impaired TPA responsiveness (see Figure 4C ).
Conclusions and implications
Our results have supplied evidence for a composite exonic splice regulator which is responsive to cell signalling. Retention or excision of CD44 exon v5 from pre-mRNA is regulated by distinct types of cis-acting elements: an exon recognition element and a silencer element composed of two subdomains, L and M (see Figure 7) . Whereas subdomain L can work independently, subdomain M is able to act only in conjunction with subdomain L. Given the necessity for both silencer and enhancer elements for regulated exon inclusion in the complete exon, there currently is no definitive answer to the question of whether one of the elements or both sense phorbol ester activation. An answer can probably only be obtained after cloning of the factors binding to these elements.
We have shown previously by cell fusion experiments that trans-acting factors govern alternative splicing of CD44 pre-mRNA (König et al., 1996) . These factors could bind to the elements identified here, either directly or indirectly, or they might represent factors able to modify proteins recognizing these elements. Regulation could be established by the cooperative binding of silencer proteins to subdomains L and M of the silencer region which might impair the binding or function of positively acting factors at the exon recognition element (subdomain R) (see Figure 7) . In cells showing high constitutive inclusion of CD44 exon v5, the silencer factors might be present in very low amounts or, alternatively, they could be modified in such a way that either their RNA binding or their interaction with enhancer factors is abolished. In cells in which the exon is skipped, the silencer factors would bind to their cognate elements and thereby displace the exon recognition factors or interfere with their activating function. Activation of signal transduction pathways such as PKC or Ras signalling could modify either the silencer factors, the enhancer factors or both, thus affecting their RNA-binding capacity or their ability to interact with each other and with components of the splicing machinery.
Changes in phosphorylation recently have been shown to affect protein-protein and protein-RNA interactions of SR proteins (Tacke et al., 1997; Xiao and Manley, 1997) and RNA binding of heterogeneous nuclear ribonucleo-proteins (hnRNPs) (Mayrand et al., 1993; Municio et al., 1995) . Interestingly, some hnRNPs are known to be phosphorylated in response to extracellular signals (Municio et al., 1995; van Seuningen et al., 1995) . Furthermore, SR protein kinases can affect redistribution of SR proteins in the nucleus (Gui et al., 1994; Colwill et al., 1996) , and one of them, Clk1, has been shown to influence alternative splice patterns in vivo (Duncan et al., 1997) . Whether the activity of SR protein kinases can be regulated by signal transduction pathways is as yet unknown. Both SR proteins and hnRNPs can bind RNA in a cooperative fashion (Kumar et al., 1990; Lynch and Maniatis, 1996; McAfee et al., 1996) and can affect alternative splicing positively and negatively (for recent reviews, see Chabot, 1996; Wang and Manley, 1997) , making them candidates for the factors postulated here to regulate alternative splicing.
The composite exonic splice regulator, demonstrated here for CD44 exon v5, may represent a prototype of RNA elements used in controlling alternative splicing. A juxtaposition of exon recognition elements and exonic silencer sequences has been described previously for the fibronectin EDA exon (Caputi et al., 1994) and for viral transcripts of human immunodeficiency virus type 1 and bovine papilloma virus type 1 (Amendt et al., 1995; Staffa and Cochrane, 1995; Zheng et al., 1996) . However, the composite splice unit in CD44 exon v5 described here represents, to our knowledge, the first example of splice regulatory elements responsive to cell signalling. The coupling of signal transduction to alternative splicing by such RNA elements could be the basis for establishing tissue-specific splice patterns during development and for switching splice patterns under physiological or pathological conditions.
Materials and methods
Cell culture and transfections LB17 2.3 is a subline derived from the murine LB17 T-lymphoma cell line (Zahalka et al., 1995) ; culture conditions were as described elsewhere (Zahalka et al., 1995) . KLN205 mouse carcinoma cells (ATCC CRL-1453), 293 human embryonal kidney cells (ATCC CRL-1573), HT-3 human cervix carcinoma cells (ATCC HTB-32), KG-1 human acute myelogenic carcinoma cells (ATCC CRL-8031) and HaCaT immortalized human keratinocytes (Boukamp et al., 1988) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine, at 37°C and 6% CO 2 . KLN205, HaCaT and HT-3 cells were transfected with 10 µg of plasmid DNA by electroporation using a Bio-Rad Gene Pulser (0.2 cm gap cuvettes, 250 µF, 380 V for KLN205, HT-3 and HaCaT cells; 0.4 cm gap cuvettes, 960 µF, 320 V for KG-1 cells). Transfections of LB17 2.3 cells were performed using 5 µg of DNA and a polycationic reagent (SuperFect, Qiagen) according to the manufacturer's instructions. In co-transfection experiments, 4 µg of the minigene plasmid were co-transfected with either 4 µg of RSV-ras (leucine 61) (Medema et al., 1991) or the empty expression vector.
RT-PCR analysis
RT-PCR analysis of the minigene transcripts was performed as described (König et al., 1996) using 0.6 µg of DNase-treated cytoplasmic RNA and the insulin exon primers N5Ins GAGGGATCCGCTTCCTGCCCC and N3Ins CTCCCGGGCCACCTCCAGTGCC. Thirty PCR cycles (60 s at 94°C, 60 s at 59°C, 90 s at 72°C) were performed using cDNA of transfected KLN205 cells and 35 cycles for cDNA of transfected LB17 2.3 cells. PCR reactions were in the linear phase (not in the plateau phase) under theses conditions, as verified by using different amounts of cDNA. Cytoplasmic RNA was prepared according to Wirth and Baltimore (1988) . Exon-specific RT-PCRs (24 cycles) were performed with rat CD44 primers as described previously (König et al., 1996) . Only for exon v6, the 5Ј primer pv6mouse (CTAATAGTACAGCAGAA-GCA) was used.
Plasmid constructions and linker-scan mutagenesis CD44 v5 minigene construct. A 3 kb fragment of the mouse genomic CD44 sequence, containing exons v4, v5 and corresponding intron sequences was cloned into the exon-trap vector pL53In (Mobitec). The 3 kb genomic sequence was cut out as a NotI-EcoRV fragment from a genomic CD44 subclone in pBluescript (kindly provided by Jürgen Moll) and cloned into the multiple cloning site (NotI-SacI blunt) of pL53In. Subsequently, exon v4 was deleted by PCR, resulting in the construct pETv5.
pETv5 blue and pETv5amp. A 105 bp SacI-KpnI (blunt) fragment of the pBluescript SK (Stratagene) polylinker sequence (for v5blue) or a 111 bp ScaI-PvuI (blunt) fragment from the bacterial ampicillin resistance gene (for v5amp) were cloned into the MluI site (blunt) of pETls1/11. pETls1/11 was obtained by PCR-mediated deletion of the v5 sequence from pETv5 except for the four 5Ј most and the three 3Ј most nucleotides. By the PCR primers, a 10 bp MluI linker had been introduced.
Linker scan mutants pETv5ls1-ls11. Ten base pairs of the 117 bp v5 exon (see Figure 4A ) were replaced consecutively with a 10 bp MluI linker (CGACGCGTCG) by PCR. Eleven PCR primer pairs were used that deleted 10 bp each throughout exon v5 (except for the four 5Ј most and the three 3Ј most nucleotides). At their 5Ј ends, the primers contained the 10 bp MluI linker sequence. Primer sequences and further details are available on request.
Deletion mutants ∆L,∆M and ∆R. Mutants were generated by combining corresponding PCR fragments used for linker-scan mutagenesis. In each mutant, 40 bp were removed from the 5Ј (∆L, segments ls1-ls4; see Figure 4A ), the middle (∆M, ls5-ls8) or the 3Ј (∆R, ls8-ls11) portion of the original v5 sequence (whereby 10 bp of the deleted 40 bp were replaced by the MluI linker).
Mutants ∆Lblue, ∆Mblue, ∆Rblue, ∆La30, ∆Ma30 and∆Ra30. To obtain the ∆blue mutants, the oligonucleotides 5Ј-CGCGAGCTTGATATCG-AATTCCTGCAGCCC-3Ј (upper strand) and 5Ј-CGCGGGGCTGCA-GGAATTCGATATCAAGCT-3Ј (lower strand), derived from the polylinker region of pBluescript SK (Stratagene), were cloned into the MluI site of the ∆L, ∆M and ∆R constructs. The ∆a30 mutants were generated similarly, using the oligonucleotides 5Ј-CGCGTAT-CATGGTTATGGCAGCACTGCATA-3Ј (upper strand, derived from the non-coding strand of the bacterial ampicillin resistance gene) and 5Ј-CGCGTATGCAGTGCTGCCATAACCATGATA-3Ј (lower strand).
Mutant pETv5bls7. An MluI-EcoNI fragment from linker-scan mutant ls7 (see Figure 4A ), spanning the 3Ј 43 bp of exon v5 and 109 bp of the downstream intron, was used to replace a corresponding SmaI-EcoNI fragment of pETv5blue, spanning the 3Ј 46 bp of the v5blue exon plus the 109 bp intron sequence.
Mutants pETv5ls1/8 and pETls1/8bl20. pETls1/8 was obtained by PCRmediated deletion of the v5 sequences spanning linker-scan segments ls1-ls8 (see Figure 4A ). By the PCR primers, a 10 bp MluI linker had been introduced. To generate pETls1/8bl20, the oligonucleotides 5Ј-CGCGATATCGAATTCCTGCAGCCC-3Ј (upper strand) and 5Ј-CGCGGGGCTGCAGGAATTCGATAT-3Ј (lower strand), derived from the pBluescript polylinker, were cloned into the MluI site of pETls1/8.
